Related Experiment Videos
A pilot study of flutamide. A new agent in the treatment of advanced prostatic cancer
The Medical Journal of Australia
|February 18, 1984
Abstract:
Flutamide, a new non-steroidal antiandrogenic agent, was administered in the treatment of five assessable patients with advanced carcinoma of the prostate. Two patients showed significant clinical benefit, one showed a reduction in his requirement for analgesia and two failed to benefit; side-effects were minimal. These results indicate the need for a controlled clinical trial of flutamide in patients with prostatic cancer.
Insights
Flutamide, a novel non-steroidal antiandrogen, showed promise in treating advanced prostate cancer. Minimal side effects were observed, warranting further clinical investigation.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced prostate cancer presents a significant therapeutic challenge.
- Non-steroidal antiandrogenic agents offer a potential treatment avenue.
Observation:
- A small cohort of five patients with advanced prostate cancer received flutamide.
- The study assessed clinical benefit and side effects of flutamide treatment.
Findings:
- Two patients experienced significant clinical benefit from flutamide.
- One patient required less pain medication, while two patients did not respond.
- Reported side effects associated with flutamide were minimal.
Implications:
- Flutamide demonstrates potential efficacy in a subset of advanced prostate cancer patients.
- These preliminary findings support the need for rigorous, controlled clinical trials.
- Further research is crucial to establish flutamide's role in prostate cancer management.